Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am

Related Keywords

Argentina ,Rio De Janeiro ,Estado Do Rio ,Brazil ,Funder ,Midtjylland ,Denmark ,France ,Spain ,Boston ,Massachusetts ,United States ,Germany ,Turkey ,Taiwan ,Cyprus ,Copenhagen ,Køavn ,Portugal ,Canada ,Sweden ,New Zealand ,Italy ,Cidade Universitaria ,Australia ,American ,Alnylam Pharmacauticals ,Marques Jr ,Clementino Fraga Filho ,Waddington Cruz ,Ionis Astrazeneca ,Rodolpho Paulo Rocco ,Intellia Regeneron ,Research To Practice ,Pfizer ,American Academy Of Neurology Annual Meeting ,Ionis Pharmaceuticals ,Ionis Pharmaceuticals Inc ,University Of Rio De Janeiro ,Aptitude Health ,Bristol Myers Squibb ,Novo Nordisk ,Group Information ,Astrazeneca ,Drug Administration ,Alnylam Pharmaceuticals ,Peripheral Nerve Society Annual Meeting ,International Council For Harmonisation ,Johnson ,Mayo Clinic Peripheral Nerve Research Laboratory ,American Society Of Hematology ,Item Short Form ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire ,Diabetic Neuropathy ,Trials Register ,International Council ,Study Design ,Meso Scale Discovery ,Mayo Clinic ,Peripheral Nerve Research Laboratory ,Item Short Form Survey ,Medical Dictionary ,Regulatory Activities ,Size Calculation ,Post Hoc Analyses ,Hospital Universit ,Federal University ,Drs Coelho ,Interest Disclosures ,American Society ,Akcea Therapeutics ,Intellia Therapeutics ,Hoffmann La Roche ,Physicians Education Resource ,American Academy ,Neurology Annual Meeting ,